CARFILZOMIB |
PR-171 |
KYPROLIS |
KYPROLIS® |
drugbank:08889 |
rxcui:1302966 |
pubchem.compound:11556711 |
chemidplus:868540-17-4 |
chembl:CHEMBL451887 |
FDA Approval | Multiple myeloma |
Drug Class | Small molecule inhibitor |
FDA Approval | not approved |
Drug Class | Small molecule |
Drug Indications | antineoplastic agent |
inhibitor (inhibitory) |
Direct Interaction | yes |
Mechanism of Interaction | 26S proteosome inhibitor |
inhibitor (inhibitory) |
Mechanism of Interaction | 26S proteosome inhibitor |
Direct Interaction | yes |
Trial Name | Carfilzomib |
inhibitor (inhibitory) |
Mechanism of Interaction | 26S proteosome inhibitor |
Direct Interaction | yes |
inhibitor (inhibitory) |
Mechanism of Interaction | 26S proteosome inhibitor |
Direct Interaction | yes |
inhibitor (inhibitory) |
Mechanism of Interaction | 26S proteosome inhibitor |
Direct Interaction | yes |
inhibitor (inhibitory) |
Mechanism of Interaction | 26S proteosome inhibitor |
Direct Interaction | yes |
inhibitor (inhibitory) |
Mechanism of Interaction | 26S proteosome inhibitor |
Direct Interaction | yes |
inhibitor (inhibitory) |
Mechanism of Interaction | 26S proteosome inhibitor |
Direct Interaction | yes |
inhibitor (inhibitory) |
Mechanism of Interaction | 26S proteosome inhibitor |
Direct Interaction | yes |
inhibitor (inhibitory) |
Mechanism of Interaction | 26S proteosome inhibitor |
Direct Interaction | yes |
inhibitor (inhibitory) |
Mechanism of Interaction | 26S proteosome inhibitor |
Direct Interaction | yes |
inhibitor (inhibitory) |
Mechanism of Interaction | 26S proteosome inhibitor |
Direct Interaction | yes |
inhibitor (inhibitory) |
Mechanism of Interaction | 26S proteosome inhibitor |
Direct Interaction | yes |
inhibitor (inhibitory) |
Direct Interaction | yes |
Mechanism of Interaction | 26S proteosome inhibitor |
inhibitor (inhibitory) |
Direct Interaction | yes |
Mechanism of Interaction | 26S proteosome inhibitor |
inhibitor (inhibitory) |
Mechanism of Interaction | 26S proteosome inhibitor |
Direct Interaction | yes |
inhibitor (inhibitory) |
Mechanism of Interaction | 26S proteosome inhibitor |
Direct Interaction | yes |
inhibitor (inhibitory) |
Direct Interaction | yes |
Mechanism of Interaction | 26S proteosome inhibitor |
inhibitor (inhibitory) |
Mechanism of Interaction | 26S proteosome inhibitor |
Direct Interaction | yes |
Novel drug target | Established target |
inhibitor (inhibitory) |
Mechanism of Interaction | 26S proteosome inhibitor |
Direct Interaction | yes |
inhibitor (inhibitory) |
Mechanism of Interaction | 26S proteosome inhibitor |
Direct Interaction | yes |
inhibitor (inhibitory) |
Mechanism of Interaction | 26S proteosome inhibitor |
Direct Interaction | yes |
inhibitor (inhibitory) |
Mechanism of Interaction | 26S proteosome inhibitor |
Direct Interaction | yes |
inhibitor (inhibitory) |
Mechanism of Interaction | 26S proteosome inhibitor |
Direct Interaction | yes |
inhibitor (inhibitory) |
Mechanism of Interaction | 26S proteosome inhibitor |
Direct Interaction | yes |
inhibitor (inhibitory) |
Direct Interaction | yes |
Mechanism of Interaction | 26S proteosome inhibitor |
inhibitor (inhibitory) |
Mechanism of Interaction | 26S proteosome inhibitor |
Direct Interaction | yes |
inhibitor (inhibitory) |
Direct Interaction | yes |
Mechanism of Interaction | 26S proteosome inhibitor |
inhibitor (inhibitory) |
Mechanism of Interaction | 26S proteosome inhibitor |
Direct Interaction | yes |
inhibitor (inhibitory) |
Direct Interaction | yes |
Mechanism of Interaction | 26S proteosome inhibitor |
inhibitor (inhibitory) |
Direct Interaction | yes |
Mechanism of Interaction | 26S proteosome inhibitor |
inhibitor (inhibitory) |
Trial Name | Carfilzomib |
Novel drug target | Established target |
Direct Interaction | yes |
inhibitor (inhibitory) |
Mechanism of Interaction | 26S proteosome inhibitor |
Direct Interaction | yes |
inhibitor (inhibitory) |
Mechanism of Interaction | 26S proteosome inhibitor |
Direct Interaction | yes |
inhibitor (inhibitory) |
Mechanism of Interaction | 26S proteosome inhibitor |
Direct Interaction | yes |
inhibitor (inhibitory) |
Direct Interaction | yes |
Mechanism of Interaction | 26S proteosome inhibitor |
inhibitor (inhibitory) |
Mechanism of Interaction | 26S proteosome inhibitor |
Direct Interaction | yes |
inhibitor (inhibitory) |
inhibitor (inhibitory) |
inhibitor (inhibitory) |
inhibitor (inhibitory) |
inhibitor (inhibitory) |
inhibitor (inhibitory) |
inhibitor (inhibitory) |
inhibitor (inhibitory) |
inhibitor (inhibitory) |
inhibitor (inhibitory) |
inhibitor (inhibitory) |
inhibitor (inhibitory) |
inhibitor (inhibitory) |
inhibitor (inhibitory) |
inhibitor (inhibitory) |
inhibitor (inhibitory) |
inhibitor (inhibitory) |
Mechanism of Interaction | 26S proteosome inhibitor |
Direct Interaction | yes |
PR-171 | Development Name |
CARFILZOMIB | Generic Name |
KYPROLIS | Trade Name |
Drug Class | Small molecule inhibitor |
FDA Approval | Multiple myeloma |
Drug Indications | antineoplastic agent |
Drug Class | Small molecule |
FDA Approval | not approved |
CHEMBL451887 | ChEMBL Drug ID |
D00UVA | TTD Drug ID |